Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

Recombinant Interleukin 4 was administered by subcutaneous injection at daily doses of 0.5, 1.0 or 5.0 micrograms kg-1 to nine patients as part of a Phase I Dose Toxicity Study. Dose limiting toxicity was reached at 5 micrograms kg-1 day-1. Symptoms of toxicity included fatigue, 'flu like sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilleece, M. H., Scarffe, J. H., Ghosh, A., Heyworth, C. M., Bonnem, E., Testa, N., Stern, P., Dexter, T. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1992
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977892/
https://www.ncbi.nlm.nih.gov/pubmed/1637669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977892/
https://www.ncbi.nlm.nih.gov/pubmed/1637669

Ejemplares similares